Cantor Fitzgerald reissued their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a report released on Wednesday morning, Benzinga reports. Cantor Fitzgerald currently has a $128.00 price objective on the biotechnology company’s stock. Several other equities research analysts have also commented on SRPT. Morgan Stanley cut their price target on shares […]
Cantor Fitzgerald Reiterates Neutral Rating for Sarepta Therapeutics (NASDAQ:SRPT) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
M&T Bank Corp increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 13.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,582 shares of the biotechnology company’s stock after acquiring an additional 411 shares during the quarter. […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its target price lowered by equities research analysts at Royal Bank of Canada from $155.00 to $151.00 in a report released on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Royal Bank of Canada’s target price indicates a potential upside […]
Capula Management Ltd bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 11,627 shares of the biotechnology company’s stock, valued at approximately $1,409,000. Other hedge funds and other institutional investors have also modified their holdings of […]